[go: up one dir, main page]

ATE103982T1 - Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus. - Google Patents

Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.

Info

Publication number
ATE103982T1
ATE103982T1 AT91903050T AT91903050T ATE103982T1 AT E103982 T1 ATE103982 T1 AT E103982T1 AT 91903050 T AT91903050 T AT 91903050T AT 91903050 T AT91903050 T AT 91903050T AT E103982 T1 ATE103982 T1 AT E103982T1
Authority
AT
Austria
Prior art keywords
blood factors
expressing
virus used
vaccina virus
recombinantly manufactured
Prior art date
Application number
AT91903050T
Other languages
English (en)
Inventor
Falko-Guenter Falkner
Ross T A Macgillivray
Walter Bodemer
Friedrich Scheiflinger
Johann Eibl
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Application granted granted Critical
Publication of ATE103982T1 publication Critical patent/ATE103982T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Auxiliary Devices For Machine Tools (AREA)
  • Gear Processing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT91903050T 1990-01-26 1991-01-24 Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus. ATE103982T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90101623 1990-01-26
PCT/EP1991/000139 WO1991011519A1 (en) 1990-01-26 1991-01-24 Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process

Publications (1)

Publication Number Publication Date
ATE103982T1 true ATE103982T1 (de) 1994-04-15

Family

ID=8203546

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91903050T ATE103982T1 (de) 1990-01-26 1991-01-24 Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.

Country Status (12)

Country Link
EP (1) EP0512011B1 (de)
JP (1) JP2549224B2 (de)
AT (1) ATE103982T1 (de)
CA (1) CA2073859A1 (de)
CS (1) CS17291A2 (de)
DE (2) DE69101634D1 (de)
DK (1) DK0512011T3 (de)
ES (1) ES2052368T3 (de)
FI (1) FI923347A0 (de)
HU (1) HUT63459A (de)
NO (1) NO922953L (de)
WO (1) WO1991011519A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229390T2 (de) * 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
US5527692A (en) * 1991-12-31 1996-06-18 Zymogenetics, Inc. Methods for producing thrombin
CA2125783C (en) * 1991-12-31 2003-03-25 Richard D. Holly Methods for producing thrombin
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US6110721A (en) * 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DK1257295T3 (da) 2000-02-11 2009-08-10 Bayer Healthcare Llc Faktor VII eller VIIA-lignende molekyler
EP1136553A1 (de) * 2000-03-22 2001-09-26 Octagene GmbH Herstellung von rekombinanten Blutgerinnungsfaktoren in humanen Zellinien
EP1460131A3 (de) * 2000-03-22 2005-06-01 Octagene GmbH Herstellung von rekombinanten Blutgerinnungsfaktoren in humanen Zellinien
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
PL373728A1 (en) 2002-04-30 2005-09-05 Maxygen Holdings Ltd. Factor vii or viia polypeptide variants
DK1608745T3 (da) 2003-03-20 2009-06-15 Bayer Healthcare Llc FVII eller FVIIa-Varianter
WO2004111242A1 (en) 2003-06-19 2004-12-23 Maxygen Holdings Ltd. FACTOR VII OR VIIa GLA DOMAIN VARIANTS
JP6245299B2 (ja) * 2016-04-27 2017-12-13 バクスアルタ ゲーエムベーハー 組換え安定細胞クローン、その産生およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
EP0289586A4 (de) * 1986-11-17 1990-04-10 New England Medical Ct Steigerung der gamma-carboxylation von rekombinanten, vitamin-k-abhängigen proteinen.
JPH03501921A (ja) * 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
DE3813093A1 (de) * 1988-04-19 1989-11-09 Immuno Ag Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants

Also Published As

Publication number Publication date
DE69101634T2 (de) 1994-08-18
DK0512011T3 (da) 1994-05-09
HU9202435D0 (en) 1992-10-28
ES2052368T3 (es) 1994-07-01
EP0512011B1 (de) 1994-04-06
NO922953D0 (no) 1992-07-24
DE69101634D1 (de) 1994-05-11
CS17291A2 (en) 1991-09-15
WO1991011519A1 (en) 1991-08-08
HUT63459A (en) 1993-08-30
JPH05507401A (ja) 1993-10-28
JP2549224B2 (ja) 1996-10-30
CA2073859A1 (en) 1991-07-27
DE69101634T4 (de) 1994-12-01
FI923347A (fi) 1992-07-23
EP0512011A1 (de) 1992-11-11
FI923347A0 (fi) 1992-07-23
NO922953L (no) 1992-09-04

Similar Documents

Publication Publication Date Title
ATE103982T1 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
EP0158277A3 (de) Implantierbare Zubereitungen von regulatorischen Peptiden mit gesteuerter Freisetzung und Verfahren zur ihrer Herstellung
DE68928956D1 (de) Verfahren zur Herstellung von optisch aktivem 1,3-Butanediol
ATE110412T1 (de) Translation von mrna.
DK322188D0 (da) Fremgangsmaade til fremstilling af protein
ATE196507T1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
FI852522A0 (fi) Menetelmä tymopentiinianalogien valmistamiseksi
ATE73348T1 (de) Thymidinkinase-deletionsmutanten von bovinem herpesvirus-1, diese enthaltende impfstoffe gegen bovine rhinotracheitis und verfahren zu deren herstellung und verwendung.
DE3773963D1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
ATE6402T1 (de) Verfahren zur herstellung von hepatitis b oberflaechenantigen.
UA35639C2 (uk) Спосіб одержання композиції очищеного капсидного білка вірусу папіломи людини
ATE130198T1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
DE59101580D1 (de) Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.
DE69132472D1 (de) Verfahren zur Herstellung von optisch aktivem 1,3-Butandiol
NO180636C (no) Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1
DE69129747D1 (de) In lösung bringen von proteinen in aktiver form
HUP9901161A2 (hu) Módosított aktivitású hibrid VIII. faktor
DE68920777D1 (de) Fluor enthaltende Copolymere, Verfahren zur Herstellung davon und Vernetzungszusammensetzungen.
DE58902281D1 (de) Verfahren zur gemeinschaftlichen herstellung von 3-dialkylaminopropionitrilen, bis-(2-cyanoethyl)-ether und gewuenschtenfalls ethylencyanhydrin.
KR910003095A (ko) 사람의 단백질 c변이체 및 이의 제조방법
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
ES2014042A6 (es) Un procedimiento para la preparacion de una composicion de 1-(2'-desoxi -2' fluor -b- d- arabinofuranosil) -5-etiluracilo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee